As the biotech industry faces growing complexity in regulatory expectations and clinical trial innovation, oncology developers must adopt smarter, more agile strategies to advance their pipelines. Panel experts will explore how companies can proactively navigate global regulatory submission plans, including best practices for engaging with multiple health authorities early in development. Speakers will discuss optimizing interactions with the FDA to secure timely feedback and how to align these approaches with global development strategies. Attendees will gain insight into seeking early or concurrent international regulatory input and how this can de-risk global programs and accelerate time to approval. This session is designed to equip leaders with the tools needed to thrive in today’s oncology development landscape. Sponsored by: Parexel